Giprobiosintez

As of September 2020, the main activity of the company is scientific research and development in the field of biotechnology.

History

2026: TATNEFT bought 30% of Giprobiosynthesis

At the end of January 2026, it became known that TATNEFT increased its stake in the biotechnological company Giprobiosynthesis to 30%. The transaction was carried out through an increase in the authorized capital.

Giprobiosynthesis develops a modern industrial technology for the production of microbial protein based on natural gas. At the same time, the developments of biotechnological enterprises of the USSR are used in conjunction with modern innovative solutions. In 2017, Giprobiosynthesis for the first time in Russia received an experimental batch of microbial biomass from non-food raw materials (methane) using the producer strain - Methylococcus capsulatus GBS-15 its own selection.

𝓲

Фото: Freepik

The production of bioprotein is an example of the synergy of TATNEFT's traditional business with such a promising direction as biotechnology, and one of the projects of the circular economy, the Russian oil company says.[1]

2024

In 2024, TATNEFT and Giprobiosynthesis received a positive conclusion from the Main Directorate of State Expertise for the construction of a microbial protein production plant in order to obtain a protein based on bacteria growing on methane contained in natural gas. We are talking about the production of the microbial protein Dreamfeed ("DRIMFID") - this is a feed supplement for balancing and enriching the diets of piglets, broiler chickens, cattle and fish with protein.

2022

TATNEFT entered the capital of Giprobiosynthesis in 2022, acquiring a 10% stake in the structure of this company after an increase in the authorized capital by 13.5 million rubles. In August 2023, a controlling stake in Giprobiosynthesis, owned by KZPIF Sintez, was transferred to the authorized capital of Argument JSC. And in March 2024, TATNEFT invested an additional 16.7 million rubles in the authorized capital of the biotechnology company, bringing its share to 20%. As part of the new deal, the package has been increased by another 10%.^[2]

Notes